Today June 2nd, 2022, Nanologica AB (publ) held its annual general meeting for the financial year 2021, where the following resolutions were passed.
Adoption of income statement and balance sheet for the financial year 2021 and disposition of result
The annual general meeting adopted the income statement and balance sheet for the company and for the group in accordance with the presented accounting documents, and resolved, in accordance with the board's proposal, that the accumulated loss of SEK -46,224,712 be carried forward. The decision thus means that no dividend will be paid for the financial year 2021.
Discharge from liability
The annual general meeting discharged the members of the board of directors and the CEO from liability for the fiscal year 2021.
Board of directors and board fees
In accordance with the nomination committee's proposal, the ordinary board members Gisela Sitbon, Mattias Bengtsson, Eva Byröd, Thomas Eldered, Tomas Kramar, Anders Rabbe and Lena Torlegård were re-elected as members of the board, all for a term of office extending until the end of the next annual general meeting. Gisela Sitbon was re-elected chairperson of the board.
Furthermore, the annual general meeting resolved on board fees and fees for committee work in accordance with the nomination committee's proposal as follows: SEK 290,000 to the chairperson of the board, SEK 170,000 to each of the other board members, SEK 50,000 to the chairperson of the audit committee, SEK 30,000 to each of the other members of the audit committee, SEK 25,0000 to the chairman of the remuneration committee and SEK 15,000 to each of the other members of the remuneration committee. The resolution means that the level of remuneration for the chairperson of the board and board members has been adjusted compared to the previous term.
The auditor and auditor's fee
The meeting resolved, in accordance with the nomination committee's proposal, to re-elect the registered the accounting firm BDO AB as auditor of the company for the period until the end of the next annual general meeting, with authorized public accountant Niclas Nordström as auditor in charge. Remuneration to the auditor shall be paid in accordance with approved invoice.
Nomination committee and nomination committee instruction
The annual general meeting resolved to establish a nomination committee and nomination committee instructions in accordance with the nomination committee's proposal.
Guidelines for remuneration to senior executives
The annual general meeting resolved, in accordance with the board's proposal, to adopt guidelines for remuneration to senior executives.
Remuneration report for the financial year 2021
The annual general meeting resolved to approve the remuneration report for the financial year 2021.
Authorization for the board of directors to resolve on issuing of new shares
In accordance with the board's proposal, the annual general meeting resolved to authorize the board of directors to, on one or more occasions during the period until the next annual general meeting, resolve on the issue of shares, convertibles and/or warrants with or without deviation from the shareholders' preferential rights and with or without provision for non-cash consideration and/or set-off or otherwise with conditions. the board of directors shall, in the case of issues carried out with deviation from the shareholders' preferential rights, not be able to make a decision that means that the amount by which the share capital is increased corresponds to more than twenty (20) percent of the total share capital in the company – at the time when the authorization is first used – after the issue has been carried out.
Proposal on incentive program for CEO, management and other employees withdrawn
On May 31, 2022, it was announced that the board had decided to withdraw the proposal for a new incentive program for the CEO, management and other employees as presented in the notice of the meeting. The reason for the withdrawal is that the board of directors wishes to await the outcome of the option programs that expire on July 1, 2022. Depending on the outcome, a new option program may be proposed later this year.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed on Nasdaq Stockholm since March 29, 2022. For further information, please visit www.nanologica.com.
This is a translation of the original press release in Swedish. In case of any discrepancies, the original press release in Swedish has precedence.